Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of KW-6500 in Parkinson's Disease
NCT01063621Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Jan 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of KW-6500 in Parkinson's disease (PD), sponsored by Kyowa Kirin. Primary endpoint: Adverse events and related adverse events at 52 weeks. Started Jan 2010; status: completed.
02
Drugs
KW-6500
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01063621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01063621.